ESSA Announces Filing of Prospectus Supplement and an Update to Previously Announced Equity Offering
Summary
The price and the number of Units were determined by negotiation between the Company and the Canadian Agent in the context of the market.The net proceeds will also be used for the interest and principal payments on the Companys outstanding debt and for working capital and general corporate purposes.The Company expects to close the Offering on or about December 21, 2017, or such other date as may be mutually agreed to by the Company and the Canadian Agent, subject to satisfaction of customary closing conditions, including, but not limited to, the receipt of all necessary stock exchange approvals, such as the conditional approval of the TSXV and NASDAQ.Such statements reflect ESSAs current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies.In making forward looking statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSAs financial projections; (ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market and economic conditions.